BNTX

BioNTech SE BNTX

NasdaqLarge CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$2.87B

Quarter to Dec 31

Net income

$-1.14B

Quarter to Dec 31

Free cash flow

$280.90M

Quarter to Dec 31

Operating margin

-48.9%

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$4.36B total
FMR LLC
$704.56M+32.6%
PRIMECAP MANAGEMENT CO/CA/
$350.99M-0.6%
DODGE & COX
$342.20M0.0%
FLOSSBACH VON STORCH SE
$207.14M-39.5%
T. Rowe Price Investment Management, Inc.
$192.19M-64.7%
BlackRock, Inc.
$172.60M+11.9%
Temasek Holdings (Private) Ltd
$140.14M0.0%
BNP PARIBAS FINANCIAL MARKETS
$122.78M-20.1%
Logos Global Management LP
$94.45MNew
GSK plc
$82.80M0.0%
FIRST TRUST ADVISORS LP
$73.65M-5.8%
Davern Capital Partners, LP
$70.21M+147.3%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME
$69.25M-5.1%
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
$63.06M+1.1%
Long Focus Capital Management, LLC
$58.06M0.0%
BAILLIE GIFFORD & CO
$55.12M-32.9%
GOLDMAN SACHS GROUP INC
$54.89M+509.2%
VICTORY CAPITAL MANAGEMENT INC
$50.23M+13.2%
FRANKLIN RESOURCES INC
$50.21M+40.3%
Candriam S.C.A.
$46.25M+1.9%
MORGAN STANLEY
$45.79M+2.0%
BANK OF AMERICA CORP /DE/
$45.24M-46.2%
TANG CAPITAL MANAGEMENT LLC
$43.73M0.0%
BALYASNY ASSET MANAGEMENT L.P.
$43.10M+395.6%
DekaBank Deutsche Girozentrale
$41.20M0.0%
See all 284 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

FY 2025
EDGAR

Net Income

FY 2025
EDGAR

EPS (Diluted)

FY 2025
EDGAR

Operating Margin

FY 2025
EDGAR

ROIC

FY 2025
EDGAR

Free Cash Flow

FY 2025
EDGAR

Loading ratio trend…

BNTX key financials by period

Reported revenue, net income and operating margin by fiscal year, from BioNTech SE's annual filings on SEC EDGAR.

BioNTech SE reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$2.9B$-1.1B-48.9%
FY 2024$2.8B$-665.3M-47.8%
FY 2023$3.8B$930.3M18.1%
FY 2022$17.3B$9.4B73.0%
FY 2021$19.0B$10.3B80.5%
FY 2020$482.3M$15.2M-17.1%
Source: BNTX filings on SEC EDGAR →

BNTX insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

Congress trading in BNTX

9 transactions in BNTX reported by 2 members of Congress under the STOCK Act, most recent trade Aug 7, 2025. Reported transactions, not recommendations.

All Congress stock trades →

About BioNTech SE (BNTX): stock profile, AI score and financials

BioNTech SE (BNTX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. BNTX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (FY 2025), BioNTech SE reports quarterly revenue of $2.9B, net income of $-1.1B, an operating margin of -48.9%. Top institutional holders of BNTX by reported 13-F value include FMR, PRIMECAP MANAGEMENT, DODGE & COX, based on the most recent SEC filings. BNTX trades on the Nasdaq exchange and files with the SEC under CIK 1776985. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BNTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BioNTech SE directly from SEC EDGAR.

SEC EDGAR: CIK 1776985 →